Longboard pharmaceuticals reports second quarter 2024 financial results and provides corporate updates

La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported second quarter 2024 financial results. “the first half of the year has been monumental for longboard and underpins the vision that we have been working towards since the inception of the company, which is to help a broad range of patients living.
LBPH Ratings Summary
LBPH Quant Ranking